Castle Biosciences CEO Executes $106,598 Stock Sale as Company Posts Better-Than-Expected Q4 Results
Castle Biosciences President and CEO Derek J. Maetzold sold 4,400 shares on March 26, 2026, for roughly $106,598 under a Rule 10b5-1 plan, while also exercising options for 550 shares. The company's stock has fallen since the sale, even as Castle posted stronger-than-expected fourth-quarter 2025 results and presented clinical data on its DecisionDx…